The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Germline mutations in patients with metastatic prostate cancer: A prospective cohort study in South Korea (KCSG GU20-19).
 
Joo-Hwan Park
No Relationships to Disclose
 
Inkeun Park
No Relationships to Disclose
 
Jinju Kim
No Relationships to Disclose
 
Chang Seon Lee
No Relationships to Disclose
 
Kwonoh Park
No Relationships to Disclose
 
Jin Young Kim
No Relationships to Disclose
 
Se Hyun Kim
Consulting or Advisory Role - Guardant Health; Ono Pharmaceutical; Yuhan
 
Il Hwan Kim
No Relationships to Disclose
 
Hyo Jin Lee
No Relationships to Disclose
 
Woo Kyun Bae
No Relationships to Disclose
 
Seok Jae Huh
No Relationships to Disclose
 
Miso Kim
Honoraria - Astellas Pharma; Merck; Novartis; Yuhan
Consulting or Advisory Role - Astellas Pharma; Bayer; Bayer; Boryung; Bristol-Myers Squibb/Ono Pharmaceutical; Eisai; Ipsen; Janssen; Merck; MSD; Pfizer; Roche; Yuhan
 
Min-Young Lee
No Relationships to Disclose
 
Seong Hoon Shin
No Relationships to Disclose
 
Ho Young Kim
No Relationships to Disclose
 
Byeong Seok Sohn
No Relationships to Disclose
 
In-Ho Kim
No Relationships to Disclose
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Merck; Novartis
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)